Literature DB >> 23475691

Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.

J C Cappelleri1, A G Bushmakin, J Harness, C Mamolo.   

Abstract

PURPOSE: The Physician Global Assessment (PGA) is a key measure of psoriasis frequently used in clinical trials. A psychometric validation of a three-item (erythema, induration, and scaling) PGA scale was performed using Phase 2 data.
METHODS: Confirmatory factor analysis (CFA) tested the PGA measurement model and appropriateness of equal weighting of the items. PGA test-retest reliability was assessed by estimating the intraclass correlation coefficient (ICC). Internal consistency reliability was gauged by calculating Cronbach's coefficient α (CCα). Clinically important difference (CID) was defined using the repeated measures model to estimate the relationship between PGA and Patient Global Assessment (PtGA). Known-group, convergent, and divergent validity for the PGA were also assessed.
RESULTS: 197 patients with psoriasis were randomized to tofacitinib 2, 5, 15 mg twice daily, or placebo. CFA demonstrated that the PGA measurement model fitted the data using equal weighting of the PGA items. The PGA scale demonstrated good test-retest reliability (ICC > 0.7) and internal consistency reliability (CCα > 0.8). The CID for PGA was estimated at 0.52 (95 % confidence interval: 0.47, 0.56). A robust monotonic relationship between PGA and Psoriasis Area and Severity Index (PASI) data substantiated known-group validity. Relatively high correlations of PGA with PASI and PtGA data (all correlations >0.5 except at baseline) supported convergent validity; relatively low correlations of PGA with the Pain/Discomfort Assessment and the Ocular Comfort Index supported divergent validity.
CONCLUSIONS: The three-item PGA scale has sound psychometric properties with respect to reliability and validity, with equal weighting of the items being appropriate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475691     DOI: 10.1007/s11136-013-0384-y

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  21 in total

1.  Conjunctival impression cytology and tear-film changes in patients with psoriasis.

Authors:  A A Karabulut; I S Yalvac; H Vahaboglu; A B Nurozler; S Duman
Journal:  Cornea       Date:  1999-09       Impact factor: 2.651

Review 2.  Assessing the clinical significance of single items relative to summated scores.

Authors:  Jeff A Sloan; Neil Aaronson; Joseph C Cappelleri; Diane L Fairclough; Claudette Varricchio
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

3.  Poor metrics and lost opportunity.

Authors:  Robert S Stern
Journal:  J Am Acad Dermatol       Date:  2010-10       Impact factor: 11.527

Review 4.  Understanding the minimum clinically important difference: a review of concepts and methods.

Authors:  Anne G Copay; Brian R Subach; Steven D Glassman; David W Polly; Thomas C Schuler
Journal:  Spine J       Date:  2007-04-02       Impact factor: 4.166

Review 5.  A point of minimal important difference (MID): a critique of terminology and methods.

Authors:  Madeleine T King
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

6.  A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.

Authors:  J Berth-Jones; K Grotzinger; C Rainville; B Pham; J Huang; S Daly; M Herdman; P Firth; K Hotchkiss
Journal:  Br J Dermatol       Date:  2006-10       Impact factor: 9.302

Review 7.  Psoriasis assessment tools in clinical trials.

Authors:  S R Feldman; G G Krueger
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 8.  Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies.

Authors:  Luigi Naldi
Journal:  Clin Dermatol       Date:  2010 Jan-Feb       Impact factor: 3.541

9.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.

Authors:  Richard G Langley; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

10.  Validation of the erection hardness score.

Authors:  John P Mulhall; Irwin Goldstein; Andrew G Bushmakin; Joseph C Cappelleri; Kyle Hvidsten
Journal:  J Sex Med       Date:  2007-09-21       Impact factor: 3.802

View more
  9 in total

Review 1.  Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments.

Authors:  Lori D McLeod; Joseph C Cappelleri; Ron D Hays
Journal:  Am J Clin Nutr       Date:  2016-02-10       Impact factor: 7.045

2.  Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.

Authors:  Mark Lebwohl; Stephen Tyring; Michael Bukhalo; Javier Alonso-Llamazares; Martin Olesen; David Lowson; Paul Yamauchi
Journal:  J Clin Aesthet Dermatol       Date:  2016-02-01

Review 3.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

4.  Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features.

Authors:  Karen Regina Rosso Schons; André Avelino Costa Beber; Maristela de Oliveira Beck; Odirlei André Monticielo
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

5.  Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.

Authors:  Jonathan West; Simon Ogston; John Foerster
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

6.  Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.

Authors:  Kim A Papp; Robert Bissonnette; Melinda Gooderham; Steven R Feldman; Lars Iversen; Jennifer Soung; Zoe Draelos; Carla Mamolo; Vivek Purohit; Cunshan Wang; William C Ports
Journal:  BMC Dermatol       Date:  2016-10-03

7.  A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.

Authors:  Kristina Callis Duffin; Andrew G Bushmakin; Joseph C Cappelleri; Lotus Mallbris; Carla Mamolo
Journal:  BMC Dermatol       Date:  2019-06-07

Review 8.  The Meaning and Reliability of Minimal Important Differences (MIDs) for Clinician-Reported Outcome Measures (ClinROMs) in Dermatology-A Scoping Review.

Authors:  Reinhart Speeckaert; Arno Belpaire; Sandrine Herbelet; Marijn M Speeckaert; Nanja van Geel
Journal:  J Pers Med       Date:  2022-07-18

9.  Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.

Authors:  John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel
Journal:  J Dermatolog Treat       Date:  2015-10-07       Impact factor: 3.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.